Spyre Therapeutics, Inc. SYRE Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s total current assets?
- Spyre Therapeutics, Inc. (SYRE) reported total current assets of $763.95M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s total current assets changed year-over-year?
- Spyre Therapeutics, Inc.'s total current assets increased by 34.1% year-over-year, from $569.77M to $763.95M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s total current assets?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s total current assets has grown at a 39.0% compound annual growth rate (CAGR), from $149.79M to $777.78M.
- What does total current assets mean?
- The total value of all assets that can be turned into cash within one year.
- How do you interpret total current assets?
- Higher values indicate greater financial flexibility and a longer operational runway for clinical development.
- How does total current assets compare across companies?
- Used by investors to calculate the current ratio and assess the overall liquidity position relative to industry peers.